Shriceres Bioscience Profile
Key Indicators
- Authorised Capital ₹ 1.00 M
as on 22-05-2024
- Paid Up Capital ₹ 0.10 M
as on 22-05-2024
- Company Age 8 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 230.56%
(FY 2020)
- Profit 75.17%
(FY 2020)
- Ebitda 121.73%
(FY 2020)
- Net Worth -17.51%
(FY 2020)
- Total Assets -2.24%
(FY 2020)
About Shriceres Bioscience
The Company is engaged in the Animal Husbandry Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 1.00 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Govindarajlu Premraaj, Daniel Nithyanand, and Tanzil Sayed serve as directors at the Company.
- CIN/LLPIN
U01403TZ2016PTC022388
- Company No.
022388
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
11 Mar 2016
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Coimbatore
Industry
Company Details
- Location
Salem, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Shriceres Bioscience?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Govindarajlu Premraaj  | Managing Director | 11-Mar-2016 | Current |
Board Members(2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Daniel Nithyanand | Director | 11-Mar-2016 | Current |
| Tanzil Sayed | Director | 14-Apr-2016 | Current |
Financial Performance of Shriceres Bioscience.
Shriceres Bioscience Private Limited, for the financial year ended 2020, experienced significant growth in revenue, with a 230.56% increase. The company also saw a substantial improvement in profitability, with a 75.17% increase in profit. The company's net worth observed a substantial decline by a decrease of 17.51%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Shriceres Bioscience?
Unlock access to Shriceres Bioscience's control and ownership data, Corporate Shareholding Patterns, Funding (security allotment) details, Foreign Institutional Investor information, Directors and Key Management Personnel (KMP) Remuneration, Group Structure, Overseas Direct Investment and other pertinent data.
Related Corporates (Common Directorship)
Intvet Proudcts Manufacturing Company Private LimitedActive 38 years 26 daysGovindarajlu Premraaj and Daniel Nithyanand are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Shriceres Bioscience?
Unlock and access historical data on people associated with Shriceres Bioscience, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Shriceres Bioscience, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Shriceres Bioscience's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.